- Home
- AMGN vs AMAT Comparison
AMGN vs AMAT Comparison
Compare AMGN & AMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- AMAT
- Stock Information
- Founded
- AMGN 1980
- AMAT 1967
- Country
- AMGN United States
- AMAT United States
- Employees
- AMGN N/A
- AMAT N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- AMAT Semiconductors
- Sector
- AMGN Health Care
- AMAT Technology
- Exchange
- AMGN Nasdaq
- AMAT Nasdaq
- Market Cap
- AMGN 141.6B
- AMAT 151.9B
- IPO Year
- AMGN N/A
- AMAT N/A
- Fundamental
- Price
- AMGN $272.11
- AMAT $192.05
- Analyst Decision
- AMGN Buy
- AMAT Buy
- Analyst Count
- AMGN 22
- AMAT 21
- Target Price
- AMGN $324.05
- AMAT $218.95
- AVG Volume (30 Days)
- AMGN 3.5M
- AMAT 6.3M
- Earning Date
- AMGN 02-04-2025
- AMAT 02-13-2025
- Dividend Yield
- AMGN 3.50%
- AMAT 0.83%
- EPS Growth
- AMGN N/A
- AMAT 6.17
- EPS
- AMGN 7.83
- AMAT 8.61
- Revenue
- AMGN $32,534,000,000.00
- AMAT $27,176,000,000.00
- Revenue This Year
- AMGN $20.07
- AMAT $10.26
- Revenue Next Year
- AMGN $3.59
- AMAT $8.34
- P/E Ratio
- AMGN $34.74
- AMAT $22.31
- Revenue Growth
- AMGN 21.25
- AMAT 2.49
- 52 Week Low
- AMGN $253.30
- AMAT $158.96
- 52 Week High
- AMGN $346.85
- AMAT $255.89
- Technical
- Relative Strength Index (RSI)
- AMGN 54.19
- AMAT 69.90
- Support Level
- AMGN $267.15
- AMAT $167.73
- Resistance Level
- AMGN $272.82
- AMAT $181.84
- Average True Range (ATR)
- AMGN 4.68
- AMAT 4.41
- MACD
- AMGN 2.37
- AMAT 2.62
- Stochastic Oscillator
- AMGN 75.60
- AMAT 96.44
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About AMAT Applied Materials Inc.
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.